ArticleUrologic oncology2016
Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Article in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Clinicopathological Risk Factors in Renal Cell Cancer for the Oncological Outcomes Following Nephron-Sparing Surgery: A PRISMA Systematic Review and Meta-Analysis.Frontiers in oncology · 2020Pooled it
- A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis.Medicine · 2019Pooled it
- Clinicohistopathological characteristics of renal cell carcinoma in Jordan.Future science OA · 2026Article
- Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis).Current oncology (Toronto, Ont.) · 2026Article
- The correlation between clinical and pathological features of renal cancer patients with survival after surgical intervention.Caspian journal of internal medicine · 2026Article
- Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study.Journal for immunotherapy of cancer · 2025Article
- Review
- A rare case of late chromophobe RCC metastasis with indolent course.Urology case reports · 2025Article
- Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.European urology open science · 2025Article
- Unclassified renal cell carcinoma with multi-organ metastasis treated with surgery and targeted therapy combination: a case report and literature review.BMC nephrology · 2025Review
- Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.Iranian journal of pathology · 2025Article
- Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma.Molecular immunology · 2024Article
- Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy.Insights into imaging · 2024Article
- The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms.Journal of cancer research and clinical oncology · 2024Article
- The Survival Outcomes of the Metastatic Nonclear Cell Renal Cell Carcinoma in the Immunotherapy Era: Princess Margaret Cancer Centre Experience.Journal of kidney cancer and VHL · 2024Article
- Establishment and validation of a prognostic nomogram for patients with renal cell carcinoma based on SEER and TCGA database.Translational cancer research · 2023Article
- Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma.BMC urology · 2023Article
- Sarcomatoid renal cell carcinoma: MRI features and their association with survival.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Molecular Imaging Diagnosis of Renal Cancer UsingDiagnostics (Basel, Switzerland) · 2023Review
- Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
8 authors.
Funding
Abstract
objectivesTo analyze whether the histological subtype of renal cell carcinoma (RCC) affects survival after surgical resection in contemporary patients, and if so, whether prognostic significance differs according to the type of surgical resection or tumor stage. MATERIALS AND
methodsFrom 2006 to 2014, 2,237 patients underwent surgical resection (25% radical nephrectomy and 75% partial nephrectomy [PN]) for nonmetastatic RCC at a tertiary referral center. Estimated survival function curves and Cox regression models evaluated the effect of histological subtype on recurrence-free survival (RFS) and overall survival (OS). Interaction analyses tested whether the effect of histological subtype depends on the type of surgical resection or tumor stage.
resultsPatients with RCC stage T2 or lower and those with low-grade conventional clear cell, papillary or chromophobe RCC of any stage had 5-year RFS probabilities>90%. Patients with clear cell papillary RCC stage T3 or greater had predicted 5-year RFS of 81%. However, 5-year OS probabilities were>94% for clear cell papillary RCC of any stage. High-grade conventional clear cell and papillary RCC stage T2 or lower, low-grade conventional clear cell and chromophobe RCC of any stage conferred 5-year OS probabilities of >93%. Unclassified RCC demonstrated the lowest OS probabilities at any stage. In multivariable analyses, histological subtype affected RFS (P<0.0001) and OS (P = 0.026) following surgical resection, with no differences in this association for radical nephrectomy vs. PN (RFS, P = 0.2; OS, P = 0.4), and across pathologic stages (RFS, P = 0.1; OS, P = 0.3). Compared with low-grade conventional clear cell RCC, chromophobe (hazard ratio [HR] = 0.72, 95% CI: 0.30-1.75) and papillary RCC (HR = 0.30, 95% CI: 0.09-0.97) conferred lower risk of recurrence. Chromophobe (HR = 0.67, 95% CI: 0.30-1.52) and clear cell papillary RCC (HR = 0.91, 95% CI: 0.12-6.78) conferred the lowest risk of all-cause mortality.
conclusionsIn the era of PN for RCC, histological subtype remained a significant predictor of survival, regardless of type of surgical resection or tumor stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.